^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Study of Vitamin D in Untreated Metastatic Colorectal Cancer

Excerpt:
...- KRAS wild-type and KRAS mutant patients are eligible...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Excerpt:
...- Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (e.g., cetuximab or panitumumab) required for patients with wild-type KRAS tumor...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status

Excerpt:
...OS in Participants With mCRC and a Documented KRAS Wild Type Status who Received Bevacizumab-Containing Treatment or Anti-EGFR Treatment in Routine Clinical Practice...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Avastin and chemotherapy followed by a KRAS stratified randomization to maintenance treatment for first line treatment of metastatic colorectal cancer Avastin (en antikropp) och kemoterapi följt av KRAS stratifierad randomisering till underhållsbehandling för behandling av metastatisk kolorektalcancer.

Excerpt:
...To evaluate maintenance treatment with bevacizumab+erlotinib versus bevacizumab alone in patients with KRAS WT tumors following first line chemo- and anti-angiogenetic therapy by comparing progression-free survival rate at 3 months. ...
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.

Excerpt:
...Wild-type or mutated KRAS tumor status....
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

SOX plus bevacizumab versus SOX plus cetuximab as initial treatment of recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study): A phase II randomized study.

Published date:
01/17/2023
Excerpt:
The overall response rate (ORR) for the SOX+B-mab group was 59.1%, whereas that for the SOX+C-mab group was 43.5% (p = 0.29). The disease control rate (DCR) for the SOX+B-mab group was 90.9%, whereas that of the SOX+C-mab group was 91.3% (p = 0.96). For all patients, median OS were 25.3 months (95% CI: 16.5–39.4 months) in the SOX+B-mab group and 15.5 months (95% CI: 7.30–30.4 months, p = 0.167) in the SOX+C-mab group...The safety and efficacy of SOX+B-mab and SOX+C-mab as initial treatment for unresectable CRC with wild-type KRAS were almost the same.
Secondary therapy:
SOX
DOI:
10.1200/JCO.2023.41.3_suppl.136
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases

Published date:
07/13/2021
Excerpt:
KRAS wild-type patients had a significantly better disease control rate than those with KRAS mutations in the TACE + B group.
DOI:
10.2217/hep-2020-0031
Trial ID: